Effect of the hypolipidemic drug nafenopin (2-methyl-2-(p-(1,2,3,4-tetrahydro-1-naphthyl)phenoxy)propionic acid; TPIA; SU-13,437), on the hepatic disposition of foreign compounds in the rat.
D000476:Alkanesulfonates / Q000378:metabolism; D000818:Animals; D001551:Benz(a)Anthracenes / Q000378:metabolism; D001646:Bile / Q000187:drug effects / Q000378:metabolism; D000431:Ethanol / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000033:anatomy & histology / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009255:Nafenopin / Q000494:pharmacology; D009929:Organ Size; D004364:Pharmaceutical Preparations / Q000378:metabolism*; D010879:Piperazines / Q000378:metabolism; D011342:Procainamide / Q000378:metabolism; D011422:Propionates / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D051381:Rats; D013386:Succinates / Q000378:metabolism; D013432:Sulfathiazoles / Q000378:metabolism; D013448:Sulfobromophthalein / Q000378:metabolism; D013997:Time Factors; D014316:Tritium
D000476:Alkanesulfonates; D001551:Benz(a)Anthracenes; D000960:Hypolipidemic Agents; D004364:Pharmaceutical Preparations; D010879:Piperazines; D011422:Propionates; D011506:Proteins; D013386:Succinates; D013432:Sulfathiazoles; D009255:Nafenopin; D013448:Sulfobromophthalein; D014316:Tritium; D000431:Ethanol; D011342:Procainamide